Authors
Latest:
Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLCFred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.
Latest:
Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPCFred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.
Latest:
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPCFred Saad, CQ, MD, FRCS, FCAHS, discusses next steps for the investigation of darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer.
Latest:
Fred Schumacher on Genetic Risk Factors of Prostate CancerFred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.
Latest:
Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in MelanomaFrederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.
Latest:
Platform Technology Development for Biologically Targeted Dosimetry and RadiotherapyThe ability to obtain high-quality radiobiological information about the interactions between tumor and healthy tissue, when using ionizing radiations, would contribute to the development of more effective and personalized radiotherapy treatments.
Latest:
Dr. Rapoport Describes Samsca's Mechanism of ActionFrederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).
Latest:
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCLA panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Latest:
Future Perspectives in Large B-Cell LymphomaFred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.
Latest:
Dr. Schnabel Discusses the DCIS Recurrence ScoreDr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score
Latest:
Dr Meric-Bernstam on the Efficacy of T-DXd in HER2-Expressing Solid TumorsFunda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.
Latest:
The Risk of Risk: Explaining Difficult Concepts to PatientsA key component of health literacy is the ability to understand statistics and concepts like "probability" and "risk."
Latest:
Dr. Budd on Prior Trastuzumab and Paclitaxel RegimensG. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.
Latest:
Reduce Exposure to Financial Risk With a Financial Counseling ProgramA well-tailored financial counseling program can help a practice minimize exposure to financial risks due to increasing patient responsibility.
Latest:
Dr. Mannis on Targeted Agents in the Treatment of Patients With AMLGabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).
Latest:
Updates to MONALEESA-2 Data in HR+ MBCImportant takeaways from MONALEESA-2 trial updates on overall survival data corresponding with the use of ribociclib plus letrozole, as presented at ESMO 2021.
Latest:
Dr. Chiorean on the Role of Genetic Testing in Pancreatic CancerElena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.
Latest:
Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and HobbsOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
JAK2 Mutations and JAK Inhibitors in the Management of Myeloproliferative NeoplasmsThe Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are clonal disorders characterized by common mutations, but with distinct clinical features, treatment considerations, and prognostic outlooks.
Latest:
Redefining BCLC B, Intermediate-Stage HCC: Is There a Role for Combination Systemic Therapy?BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.
Latest:
Unmet Needs in High-Risk MDSThe panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.
Latest:
Dr. Roboz on the Importance of Genomic Analysis in AMLGail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.
Latest:
Photodynamic Therapy: Looking at Treatment of Early-Stage Oral Cancer in a New LightAlthough surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.
Latest:
Dr. Morgan on the Differences in Low- and High-Risk Multiple MyelomaGareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.
Latest:
Dr. Morgan on the Future of Myeloma TreatmentGareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.
